New safety and efficacy data on the drug therapy, LUPKYNIS® (voclosporin), will be presented at the European Alliance of Associations Rheumatology (EULAR) Congress 2024 later this month. The data reinforces previous research that validates LUPKYNIS as a safe and effective treatment for people with lupus nephritis, (LN, lupus-related kidney disease). 

New analyses found that a triple immunosuppressive regimen of LUPKYNIS plus lower-dose mycophenolate mofetil (MMF) and low-dose steroids results in earlier and greater reductions in proteinuria, reduced steroid exposure, and adverse event incidence was similar to those being treated with dual immunosuppressive therapy regimens combining high-dose glucocorticoids with either higher doses of MMF or cyclophosphamide. 

Continue to follow the Lupus Foundation of America for updates on lupus drug developments, clinical trials, as well as new research presented at EULAR 2024. Learn more about LUPKYNIS.

Read the announcement